ADC Therapeutics SA Obligations, Fair Value Disclosure
ADC Therapeutics SA (ADCT) had Obligations, Fair Value Disclosure of $311.00 million as of 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Notes › Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis › Fair Value, Net Asset (Liability)
us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisObligations · last filed 2026-03-10
- 2025-12-31: Obligations, Fair Value Disclosure $311.00M.
- 2025-06-30: Obligations, Fair Value Disclosure $312.00M.
- 2025-03-31: Obligations, Fair Value Disclosure $312.00M.
- 2024-12-31: Obligations, Fair Value Disclosure $312.00M.
| Period end | Obligations, Fair Value Disclosure |
|---|---|
| 2025-12-31 | $311.00M 10-K · filed 2026-03-10 |
| 2025-06-30 | $312.00M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $312.00M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $312.00M 10-K · filed 2026-03-10 |
| 2023-12-31 | $272.90M 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |